

Avishay Sella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11037648/publications.pdf>

Version: 2024-02-01

35
papers

2,741
citations

331259

21
h-index

360668

35
g-index

35
all docs

35
docs citations

35
times ranked

3210
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
2	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 931-945.	5.1	337
3	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1574-1588.	5.1	324
4	Sarcomatoid renal cell carcinoma: Clinicopathologic. A study of 42 cases. <i>Cancer</i> , 1987, 59, 516-526.	2.0	234
5	Chemotherapy for Small Cell Carcinoma of Prostatic Origin. <i>Journal of Urology</i> , 1992, 147, 935-937.	0.2	148
6	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	0.6	137
7	Sarcomatoid renal cell carcinoma. A treatable entity. <i>Cancer</i> , 1987, 60, 1313-1318.	2.0	117
8	Cisplatin, Cyclophosphamide and Doxorubicin Chemotherapy for Unresectable Urothelial Tumors: The M. D. Anderson Experience. <i>Journal of Urology</i> , 1989, 141, 33-37.	0.2	101
9	Surgery Following Response to Interferon- γ -Based Therapy for Residual Renal Cell Carcinoma. <i>Journal of Urology</i> , 1993, 149, 19-21.	0.2	89
10	Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram. <i>Oncologist</i> , 2012, 17, 1508-1514.	1.9	83
11	COMBINATION CHEMOTHERAPY FOR METASTATIC OR LOCALLY ADVANCED GENITOURINARY SQUAMOUS CELL CARCINOMA: A PHASE II STUDY OF METHOTREXATE, CISPLATIN AND BLEOMYCIN. <i>Journal of Urology</i> , 1998, 160, 1770-1774.	0.2	79
12	Primary carcinoid of the kidney immunohistochemical and ultrastructural studies of five patients. <i>Cancer</i> , 1993, 72, 2660-2666.	2.0	70
13	Phase II Study of Interferon- γ and Chemotherapy (5-Fluorouracil and Mitomycin C) in Metastatic Renal Cell Cancer. <i>Journal of Urology</i> , 1992, 147, 573-577.	0.2	59
14	Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Oncologist</i> , 2014, 19, 51-60.	1.9	57
15	Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. <i>Cancer</i> , 1992, 69, 1286-1290.	2.0	53
16	Fine-needle aspiration cytology of sarcomatoid renal cell carcinoma: A morphologic and immunocytochemical study of 15 cases. <i>Diagnostic Cytopathology</i> , 1993, 9, 46-51.	0.5	50
17	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 1031-1037.	1.3	49
18	Circadian Infusion of Floxuridine in Patients with Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 1991, 146, 709-713.	0.2	37

#	ARTICLE	IF	CITATIONS
19	Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 428-432.	0.9	33
20	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018, 1, 467-475.	2.6	25
21	Tissue Specific DNA Methylation in Normal Human Breast Epithelium and in Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e91805.	1.1	23
22	Carpal tunnel syndrome associated with interleukin-2 therapy. <i>Cancer</i> , 1996, 77, 1189-1192.	2.0	19
23	Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 420-425.	0.9	19
24	Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. <i>Oncologist</i> , 2016, 21, 1212-1217.	1.9	17
25	Interferon Alternating with Chemotherapy for Patients with Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989, 12, 350-354.	0.6	16
26	A similar cell-specific pattern of HOXA methylation in normal and in cancer tissues. <i>Epigenetics</i> , 2010, 5, 41-46.	1.3	14
27	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. <i>Anti-Cancer Drugs</i> , 2013, 24, 431-440.	0.7	13
28	Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. <i>Prostate</i> , 2014, 74, 433-440.	1.2	13
29	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	0.9	11
30	Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?. <i>Cancer Research and Treatment</i> , 2016, 48, 281-287.	1.3	9
31	Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis. <i>Future Oncology</i> , 2015, 11, 2831-2840.	1.1	7
32	Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. <i>European Journal of Cancer</i> , 2020, 125, 153-163.	1.3	5
33	Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells. <i>Cancers</i> , 2020, 12, 2367.	1.7	3
34	Mutagen-induced Imm+ variants: the need for viable and cloned Imm+ variants for effective protection against a primary murine tumor and its metastases. <i>Clinical and Experimental Metastasis</i> , 1989, 7, 97-105.	1.7	1
35	Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 379-379.	0.8	1